Trial Profile
Combination OZURDEX & LUCENTIS vs. OZURDEX Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2018
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms COLLIDE
- 10 Aug 2018 Status changed from recruiting to discontinued.
- 23 Feb 2016 New trial record